• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Monitoring Myelofibrosis Treatment Response: Guidelines and Considerations

Opinion
Video

Aaron Gerds, MD, MS, reviews the National Comprehensive Cancer Network (NCCN) guidelines for monitoring myelofibrosis treatment response and delves into crucial aspects like patient impressions, physical examinations, and symptoms.

This is a video synopsis/summary of a Guidelines featuring Aaron Gerds, MD, MS.

Gerds clarifies that JAK inhibitors are not contraindicated in anemic patients, highlighting historical usage with ruxolitinib. He emphasizes the challenges of dose reduction, the potential impact on treatment outcomes, and the need for more thoughtful selection among the available JAK inhibitors. Gerds discusses response monitoring, underlining the significance of patient-reported outcomes, especially the patient's global impression of change. He recommends focusing on symptom improvement and palpable spleen length reduction, simplifying evaluation without the need for advanced imaging. The discussion delves into considerations for altering therapy in myelofibrosis, emphasizing the importance of timely assessment, typically within 3 to 6 months. Gerds discusses the RR6 prognostic model (response to ruxolitinib after 6 months), suggesting key questions at these intervals to guide treatment decisions. This segment provides practical insights for clinicians to navigate the nuanced aspects of JAK inhibitor therapy in myelofibrosis.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
Video 10 - "Bronchiectasis Exacerbation Management"
video 10  - "Developing Practical Solutions to Improve Cardiovascular Care"
video 10  - "Developing Practical Solutions to Improve Cardiovascular Care"
Video 6 - "Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus"
Video 13 - "Concluding Thoughts on Ph+ ALL Treatment"
Video 12 - "The Future of Ph+ ALL Treatments"
Video 2 - "Improving Long-Term Outlook: CT Scans and Underdiagnosis of Bronchiectasis"
Video 5 - "Strategies for Preventing Progression of Early-Stage Type 1 Diabetes"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.